Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$105.13 USD
-1.97 (-1.84%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $105.23 +0.10 (0.10%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
JAZZ 105.13 -1.97(-1.84%)
Will JAZZ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JAZZ
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
Why Is Jazz (JAZZ) Up 1.1% Since Last Earnings Report?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
Other News for JAZZ
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
Truist healthcare analyst holds an analyst/industry conference call
50 stocks to invest during the bull steepening – Part 2
Russell companies with the lowest tax rates expected to generate $1B in 2025 – GS